Verastem, Inc. (VSTM) belonging to the Medical sector has surged 11.34% and closed its last trading session at $2.16.
The company reported its EPS on 03/23/2017. Currently, the stock has a 1 Year Price Target of $4.38.
The consensus recommendation, according to Zacks Investment research, is 1.75. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2 respectively.
Verastem, Inc. on 03/23/2017 reported its EPS as $-0.32 with the analysts projecting the EPS of the stock as $-0.26. The company beat the analyst EPS Estimate with the difference of $-0.06. This shows a surprise factor of -23.1%.
Many analysts have provided their estimated foresights on Verastem, Inc. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.35.
Whereas they predicted High and Low Earnings Estimate as $-0.32 and $-0.39 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.22.
Analysts are also projecting an Average Revenue Estimate for Verastem, Inc. as $4000 in the Current Quarter.
For the Current Quarter, the growth estimate for Verastem, Inc. is -59.1%, while for the Next Quarter the stock growth estimate is -47.8%.
Insider Trades for Verastem, Inc. show that the latest trade was made on 23 Aug 2015 where Kauffman (Michael G), the Director completed a transaction type “Sell” in which 2070 shares were traded at a price of $6.46.
Verastem, Inc. (VSTM) has the market capitalization of $77.05 Million. The company rocked its 52-Week High of $2.25 and touched its 52-Week Low of $1.05.
The stock has Return on Assets (ROA) of -39.3 percent. Return on Equity (ROE) stands at -42.9% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 92.86 Percent. The company has Beta Value of 1.91 and ATR value of 0.18. The Weekly and Monthly Volatility stands at 6.92% and 8.53%.